Randomized controlled trialHumanClinical Trial, Phase II

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

The lancet. Diabetes & endocrinology, 2024 Mar. le Roux CW, Steen O, Lucas KJ and 3 others.

Study type

Randomized controlled trial · Clinical Trial, Phase II

Subjects

Human participants (PubMed MeSH: Humans)

Journal

The lancet. Diabetes & endocrinology

Published

2024 Mar

PubMed

PMID 38330987 ↗

DOI

10.1016/S2213-8587(23)00356-X ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Survodutide →

Indexed under

MeSH terms assigned by the National Library of Medicine.

AdolescentAdultAgedHumansMiddle AgedYoung AdultDiabetes Mellitus, Type 2Double-Blind MethodGlucagonGlucagon-Like Peptide 1Hypoglycemic AgentsObesity

Other papers on Survodutide

Randomized controlled trial · 2026

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Randomized controlled trial · 2026

Survodutide Once Weekly for the Treatment of Adults with Obesity

Journal article · 2026

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page